TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05278351

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab Combined With Cetuximab and Irinotecan
Description: Tislelizumab (an anti-PD-1 monoclonal antibody) Cetuximab (monoclonal antibody against EGFR) Irinotecan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Third-line regimens
Description: Trifluridinetipiracil or Regorafenib or Fruquintinib
Study: NCT05045950

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine -Twice Daily or Extended Release
Description: Both extended release memantine and twice daily memantine dosing will be allowed.~Twice daily dosing:~The target dose for memantine is 20 mg (10 mg divided twice daily). Dose will be escalated by 5 mg each week to a target of 10 mg twice daily (i.e., 5 mg a day on week 1, then 5 mg twice daily (BID) on week 2, then 10 mg in AM plus 5 mg in PM on week 3, followed by 10 mg in AM plus 10 mg in PM by week 4).~Extended Release Memantine:~The target dose for extended release memantine is 28 mg. Dose will be escalated by 7 mg per week to a target of 28 mg daily (i.e., 7 mg a day on week 1, then 14 mg a day on week 2, then 21 mg a day on week 3, followed by 28 mg a day by week 4).

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: WBRT utilizing the PRDR technique
Description: The total dose of 3000 cGy (30 Gy) will be divided 10 fractions of 300 cGy (3 Gy); each fraction will be delivered as a series of 20 cGy (0.2Gy) pulses separated by 3 min time intervals. 20 cGy / 3 min = 6.67 cGy/min (or 0.0667 Gy/min). Total time is determined by the fractionated series and time intervals, meaning 300cGy/20cGy = 15 division x 3 minutes = 45 minutes. Including time to set up, approximate total time per treatment session will be 60 minutes.
Study: NCT06235255

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided Imagery
Description: The participant will complete the Guided Imagery Intervention for 21 consecutive days.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Power Intervention
Description: The investigator with the subject uses the power profile generated by the PKPCT to generate goals that will positively affect functional health.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combined Guided Imagery and Cognitive Power Intervention
Description: This intervention is a combination of the Guided Imagery Intervention in tandem with the Cognitive Power Intervention
Study: NCT05063071

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir Alafenamide 25 MG
Description: After orthotopic liver transplant, all patients will receive Tenofovir Alafenamide monotherapy without HBIG for HBV Prophylaxis.
Study: NCT06273137

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive affect treatment
Description: PAT includes 15 weekly, 1-hour sessions. The treatment is composed of three modules targeting behaviors (Sessions 1-7), cognitions (Sessions 8 -10), and compassion (Sessions 11-14), with skills being reinforced in a cumulative manner in subsequent sessions. The final session in the original treatment (Session 15) addressed relapse prevention, which will be adapted to focus on further reinforcing and generalizing learned skills. The treatment includes guided activities that target different aspects of positive affectivity such as reward approach-motivation, reward learning, and reward attainment.
Study: NCT04835831

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: adapted physical activity + Dietetic advice
Description: adapted physical activity during 24 weeks
Study: NCT05375773

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PVP-I Nasal Irrigation and gargling
Description: The solution is prepared by the researcher, which contains 0.5% PVP-I and 2.27% hypertonic saline
Study: NCT05202938

Intervention type: DIAGNOSTIC_TEST
Intervention: ultrasound cardiography
Description: Ultrasound to check heart functions and systolic ejection fraction.

Intervention type: DIAGNOSTIC_TEST
Intervention: ultrasound cardiography
Description: Ultrasound to check heart functions and systolic ejection fraction.

Intervention type: DIAGNOSTIC_TEST
Intervention: ultrasound cardiography
Description: Ultrasound to check heart functions and systolic ejection fraction.

Intervention type: DIAGNOSTIC_TEST
Intervention: ultrasound cardiography
Description: Ultrasound to check heart functions and systolic ejection fraction.

Intervention type: DIAGNOSTIC_TEST
Intervention: FDG PET scan
Description: FDG venous injection and positron emission tomography scan.

Intervention type: DIAGNOSTIC_TEST
Intervention: FDG PET scan
Description: FDG venous injection and positron emission tomography scan.

Intervention type: DIAGNOSTIC_TEST
Intervention: FDG PET scan
Description: FDG venous injection and positron emission tomography scan.

Intervention type: DIAGNOSTIC_TEST
Intervention: FDG PET scan
Description: FDG venous injection and positron emission tomography scan.

Intervention type: DIAGNOSTIC_TEST
Intervention: Palmitate PET scan
Description: C11-Palmitate venous injection and positron emission tomography scan.

Intervention type: DIAGNOSTIC_TEST
Intervention: Palmitate PET scan
Description: C11-Palmitate venous injection and positron emission tomography scan.

Intervention type: DIAGNOSTIC_TEST
Intervention: Palmitate PET scan
Description: C11-Palmitate venous injection and positron emission tomography scan.

Intervention type: DIAGNOSTIC_TEST
Intervention: Palmitate PET scan
Description: C11-Palmitate venous injection and positron emission tomography scan.

Intervention type: DIAGNOSTIC_TEST
Intervention: Acetate PET scan
Description: C11-Acetate venous injection and positron emission tomography scan.

Intervention type: DIAGNOSTIC_TEST
Intervention: Acetate PET scan
Description: C11-Acetate venous injection and positron emission tomography scan.

Intervention type: DIAGNOSTIC_TEST
Intervention: Acetate PET scan
Description: C11-Acetate venous injection and positron emission tomography scan.

Intervention type: DIAGNOSTIC_TEST
Intervention: Acetate PET scan
Description: C11-Acetate venous injection and positron emission tomography scan.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sampling
Description: Collecting 20ml of venous blood.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sampling
Description: Collecting 20ml of venous blood.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sampling
Description: Collecting 20ml of venous blood.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sampling
Description: Collecting 20ml of venous blood.
Study: NCT05551442

Intervention type: PROCEDURE
Intervention: To explore the comparative study of different positioning methods in robot assisted laparoscopic pyeloplasty.
Description: The incidence of surgical positioning time and secondary berths, surgical time, intraoperative blood loss and intraoperative complications were compared among the three groups.

Intervention type: PROCEDURE
Intervention: To explore the comparative study of different positioning methods in robot assisted laparoscopic pyeloplasty.
Description: The incidence of surgical positioning time and secondary berths, surgical time, intraoperative blood loss and intraoperative complications were compared among the three groups.

Intervention type: PROCEDURE
Intervention: To explore the comparative study of different positioning methods in robot assisted laparoscopic pyeloplasty.
Description: The incidence of surgical positioning time and secondary berths, surgical time, intraoperative blood loss and intraoperative complications were compared among the three groups.

Intervention type: DEVICE
Intervention: To discuss the comparative study of different position placement methods of renal pelvis ureteroplasty on the Da Vinci robotic Xi platform
Description: To discuss the comparative study of different position placement methods of renal pelvis ureteroplasty on the Da Vinci robotic Xi platform

Intervention type: DEVICE
Intervention: To discuss the comparative study of different position placement methods of renal pelvis ureteroplasty on the Da Vinci robotic Xi platform
Description: To discuss the comparative study of different position placement methods of renal pelvis ureteroplasty on the Da Vinci robotic Xi platform

Intervention type: DEVICE
Intervention: To discuss the comparative study of different position placement methods of renal pelvis ureteroplasty on the Da Vinci robotic Xi platform
Description: To discuss the comparative study of different position placement methods of renal pelvis ureteroplasty on the Da Vinci robotic Xi platform
Study: NCT06403488

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole 2.5mg
Description: specific aromatase inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole 2.5mg
Description: specific aromatase inhibitor
Study: NCT06020729

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: General Exercises without occlusion training
Description: General Exercises as bench press, squats , maximum sprint, leg power without occlusion training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Occlusion Training
Description: In experimental sessions players will perform with occlusion training which is blood flow resistance training, 4 times a week for 4 weeks with 5 sets of 5 repetitions and then assessed pre-training and post-training values with assessment tools bench press, leg squat, leg power, maximum sprint time.This training will also improve and increase muscular strength as well as speed and physical performance in players.
Study: NCT05767476

Intervention type: DIAGNOSTIC_TEST
Intervention: Clinical and instrumental neurological assessment
Description: Participants will be involved in serial assessment:~* Neonatal Cranial Ultrasonography~* Brain magnetic resonance imaging~* Neurological assessment~* Neurodevelopmental and cognitive assessment~* Electroencephalogram (EEG)~* Motor performance assessment
Study: NCT06005129

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personality-Based Therapy
Description: Participants will be randomized to a 2- or 4-week assessment-only baseline period. After the baseline period, participants will receive the personality-based treatment module corresponding to their highest clinical elevation (i.e., neuroticism, \[low\] conscientiousness, \[low\] agreeableness). Treatment will consist of six weekly 50-60-minute sessions. After the 6-week intervention period, participants will complete a 4-week follow-up period to determine the sustainability of effects observed

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personality-Based Therapy
Description: Participants will be randomized to a 2- or 4-week assessment-only baseline period. After the baseline period, participants will receive the personality-based treatment module corresponding to their highest clinical elevation (i.e., neuroticism, \[low\] conscientiousness, \[low\] agreeableness). Treatment will consist of six weekly 50-60-minute sessions. After the 6-week intervention period, participants will complete a 4-week follow-up period to determine the sustainability of effects observed
Study: NCT06561022

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fulvestrant
Description: Fulvestrant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Fulvestrant

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abemaciclib
Description: Abemaciclib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Abemaciclib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Abemaciclib

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abemaciclib
Description: Abemaciclib

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abemaciclib
Description: Abemaciclib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Abemaciclib
Study: NCT05606744

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Eccentric exercise / Eccentric exercise with blood flow restriction
Description: Individuals will be randomized to receive eccentric exercise only, or eccentric exercise with blood flow restriction.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Eccentric exercise / Eccentric exercise with blood flow restriction
Description: Individuals will be randomized to receive eccentric exercise only, or eccentric exercise with blood flow restriction.
Study: NCT06037772

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: subcutaneous injection administration game
Description: The subcutaneous injection practice game was developed to examine nursing students' injection practice skills and its effect on their satisfaction with learning.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: control group
Description: only
Study: NCT05503901

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STN1012600 ophthalmic solution 0.002%
Description: 1 drop STN1012600 ophthalmic solution 0.002% once daily for 52 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STN1012600 ophthalmic solution 0.002%
Description: 1 drop STN1012600 ophthalmic solution 0.002% once daily for 52 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STN1012600 ophthalmic solution 0.002% and Timolol ophthalmic solution 0.5%
Description: 1 drop STN1012600 ophthalmic solution 0.002% once daily for 52 weeks and 1 drop Timolol ophthalmic solution 0.5% twice daily for 52 weeks
Study: NCT06036004

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intranasal OXT
Description: Syntocinon® contains the synthesized peptide OXT in a solution formulated to promote absorption through the nasal mucosa. Additional ingredients are E216 (propyl-4-hydroxybenzoate), E218 (methyl-4-hydroxybenzoate), and chlorobutanol hemihydrate. One bottle contains 5 ml, i.e., 200 IU of OXT in total. Each 0.1 ml nasal insulation delivers 4 IU of oxytocin.~OXT (24 IU twice daily) is given for 28 (± 2) days of treatment.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo nasal spray
Description: The placebo will contain no OXT but, otherwise, be identical to the intranasal OXT product with respect to the other ingredients.~Placebo is given twice daily for 28 (± 2) days of treatment.
Study: NCT05418309

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab Nab paclitaxel
Description: Tislelizumab 200mg will be administered on Day 1 of each cycle for 4 treatment cycles;Nab-paclitaxel 200mg will be administered on Day 2 of each cycle for 4 treatment cycles.
Study: NCT06037772

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: control group
Description: only
Study: NCT04838717

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BPG
Description: intramuscular injection of 2.4 million units

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BPG
Description: intramuscular injection of 2.4 million units

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline
Description: Oral: at a dose of 100 mg bid for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline
Description: Oral: at a dose of 100 mg bid for 14 days
Study: NCT06449937

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical local Surgery
Description: Radical local resection of liver metastases ( hepatectomy, ablation )

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Systemic therapy
Description: Chemotherapy, targeted drug therapy, immunotherapy treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Systemic therapy
Description: Chemotherapy, targeted drug therapy, immunotherapy treatment.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Interventional therapy
Description: Transcatheter arterial chemoembolization (TACE) Hepatic arterial infusion chemotherapy (HAIC)
Study: NCT05145738

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: C-Raven with avatar
Description: Computer delivered intervention with the investigators' avatar; with linkage to community health worker.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: C-Raven without avatar
Description: Computer delivered intervention without the investigators' avatar; with linkage to community health worker.
Study: NCT05451719

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fruquintinib Plus Capecitabine
Description: Fruquintinib at the dose determined in phase safety lead-in, orally once daily, on d1-21, given every 4 weeks (Q4W). Capecitabine at the dose 850mg/m2, orally twice daily, d1-7 and d15-21, given every 4 weeks (Q4W)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Capecitabine at the dose 850mg/m2, orally twice daily, d1-7 and d15-21, given every 4 weeks (Q4W)
Study: NCT05996484

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Toripalimab, 240mg, IV., D1, every 3 weeks, 4 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib hydrochloride
Description: Anlotinib Hydrochloride is a capsule in the form of 8 mg ,10 mg and 12 mg, orally, once daily, 2 weeks on/1 week off, every 3 weeks, 4 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin paclitaxel
Description: Albumin paclitaxel, 200-260 mg/m2, IV., D1, every 3 weeks, 4 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin, 60-75 mg/m2, IV., D1, every 3 weeks, 4 cycles.
Study: NCT06200350

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental group
Description: Tailored training based on the profile of each participant.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: They will continue with the traditional training.
Study: NCT05059990

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Intensity Aerobic Exercises Group
Description: Intervention Low Intensity Aerobic Exercises i.e. stationary cycle(supervised) Intensity 55-65% of HRmax Frequency 3 times a week Duration 30 min each session

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Exercises Group
Description: Intervention Upper and lower limb ROM \& stretching exercises Intensity As per tolerance Frequency 12 repetition/4sets per exercise 3 times/week Duration 30 minutes each session
Study: NCT06258642

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Liposome
Description: 70 mg/m\^2 , d1, Q2W, iv

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: 12 mg, qd, po for 2 consecutive weeks and then discontinued for 1 week.
Study: NCT04794283

Intervention type: OTHER
Intervention: Breast milk
Description: Milk substitute given during the first 24h
Study: NCT04400617

Intervention type: BEHAVIORAL
Intervention: Cross-sectional assessments to examine the relationship among sleep quality, functional/physical capacity, and cognitive performance.
Description: The first visit will consist of screening measurements. Participants will be asked to complete the following questionnaires: InterRAI Self Report Quality of Life Survey for Long Term Care Facilities (interRAI SQoL), Resident Assessment Instrument (RAI)-MDS 2.0, Global Physical Activity Questionnaire (GPAQ), Memory Complaint Questionnaire (MAC-Q), and Pittsburgh Sleep Quality Index (PSQI). At the end of this visit, the participants will be asked to wear the ActiWatch-2 (AW-2) as a wristwatch for 14 days. In the second visit, participants' height and weight will be measured and the participants will perform the following cognitive and functional tests: MoCA, Brief Visuospatial Memory Test-Revised (BVMT-R), Hopkins Verbal Learning Test-Revised (HVLT-R), Time up and Go (TUG), and Cognitive TUG (TUGcog). Finally, visit 3 will consist of on-site PSG recordings.

Intervention type: BEHAVIORAL
Intervention: Cross-sectional assessments to examine the relationship among sleep quality, functional/physical capacity, and cognitive performance.
Description: The first visit will consist of screening measurements. Participants will be asked to complete the following questionnaires: InterRAI Self Report Quality of Life Survey for Long Term Care Facilities (interRAI SQoL), Resident Assessment Instrument (RAI)-MDS 2.0, Global Physical Activity Questionnaire (GPAQ), Memory Complaint Questionnaire (MAC-Q), and Pittsburgh Sleep Quality Index (PSQI). At the end of this visit, the participants will be asked to wear the ActiWatch-2 (AW-2) as a wristwatch for 14 days. In the second visit, participants' height and weight will be measured and the participants will perform the following cognitive and functional tests: MoCA, Brief Visuospatial Memory Test-Revised (BVMT-R), Hopkins Verbal Learning Test-Revised (HVLT-R), Time up and Go (TUG), and Cognitive TUG (TUGcog). Finally, visit 3 will consist of on-site PSG recordings.
Study: NCT04608214

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alisporivir
Description: Administration of alisporivir at the dose of 600 mg p.o. BID from D1 to D14 to patients and standard of care (SOC).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care (SOC)
Description: Locally accepted regimen protocols for patient care and select agents based on the underlying diagnosis and the severity of COVID 19 (excepting e.g. azithromycin and other antibiotics listed as prohibited medications)
Study: NCT05589818

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Patients will be treated with the standard dose of pembrolizumab for the first 12 weeks of the study. After week 12 assessments, patients without objective progression of disease are eligible to transition to Q6W dosing of pembrolizumab 400mg IV. Patients will be offered this schedule, also an FDA-approved option, at the discretion of the treating physician, based on tolerability of the q3week regimen and clinician assessment of need for closer follow up intervals. Pembrolizumab will be continued until disease progression, unacceptable toxicity, withdrawal of consent, or death.